BeiGene Other Non-Cash Items 2014-2024 | ONC
BeiGene annual/quarterly other non-cash items history and growth rate from 2014 to 2024. Other non-cash items can be defined as miscellaneous non-cash adjustments to Net income.
- BeiGene other non-cash items for the quarter ending September 30, 2024 were $0.294B, a 400.03% decline year-over-year.
- BeiGene other non-cash items for the twelve months ending September 30, 2024 were $0.560B, a 30.68% increase year-over-year.
- BeiGene annual other non-cash items for 2023 were $0.007B, a 97.69% decline from 2022.
- BeiGene annual other non-cash items for 2022 were $0.309B, a 33.57% increase from 2021.
- BeiGene annual other non-cash items for 2021 were $0.231B, a 71.49% increase from 2020.
BeiGene Annual Other Non-Cash Items
(Millions of US $) |
| 2023 |
$7 |
| 2022 |
$309 |
| 2021 |
$231 |
| 2020 |
$135 |
| 2019 |
$193 |
| 2018 |
$133 |
| 2017 |
$44 |
| 2016 |
$13 |
| 2015 |
$13 |
| 2014 |
$10 |
| 2013 |
$3 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$17.962B |
$2.459B |
|
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
|
